Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

HER-2/neu Amplification Determined by Real-Time Quantitative PCR and Its Association with Clinical Outcome of Breast Cancer in Thailand

Chariyalertsak, Sunanta;Purisa, Wichai;Vinyuvat, Songkhun

  • Published : 20110700
⟨ Previous Next ⟩

Abstract

HER-2/neu has been found to be amplified or overexpressed in about 20-30% of breast cancers, in association with negative prognosticators and shortened survival. Determination of HER-2/neu status in breast-cancer patients, to select for adjuvant treatment with trastuzumab, is becoming standard breast-cancer clinical practice. This study aimed to investigate HER-2/neu status in breast-cancer by real-time quantitative polymerase chain reaction (PCR), allowing accurate and precise quantification of HER-2/neu amplification in tumor tissues. We evaluated 112 breast-cancer samples, of which 42 (37.5%) had HER-2/neu amplification. After a mean follow-up period of 71 months, HER-2/neu amplification was found to be significantly associated with increased risk of death (HR = 6.367, 95% CI = 1.787-22.684), even after adjusting for age, clinical stage, tumor size, lymph-node status, and histologic grade. These findings support a negative prognostic role for HER-2/neu in breast-cancer survival. We suggest that real-time quantitative PCR analysis of HER-2/neu amplification represents an alternative technique for establishing HER-2/neu status in routine clinical practice.

Keywords

References

  1. Akiyama T, Sudo C, Ogawara H, et al (1986). The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232, 1644-6. https://doi.org/10.1126/science.3012781
  2. Borg A, Baldetorp B, Fernö M, et al (1994). ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett, 81, 137-44. https://doi.org/10.1016/0304-3835(94)90194-5
  3. Carlomagno C, Perrone F, Gallo C, et al (1996). c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol, 14, 2702-8. https://doi.org/10.1200/JCO.1996.14.10.2702
  4. Carr JA, Havstad S, Zarbo RJ, et al (2000). The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg, 135, 1469-74. https://doi.org/10.1001/archsurg.135.12.1469
  5. Gibson UE, Heid CA, Williams PM (1996). A novel method for real time quantitative RT-PCR. Genome Res, 6, 995-1001. https://doi.org/10.1101/gr.6.10.995
  6. Gjerdrum LM, Sorensen BS, Kjeldsen E, et al (2004). Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn, 6, 42-51. https://doi.org/10.1016/S1525-1578(10)60490-4
  7. Gusterson BA, Gelber RD, Goldhirsch A, et al (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10, 1049-56. https://doi.org/10.1200/JCO.1992.10.7.1049
  8. Heid CA, Stevens J, Livak KJ, et al (1996). Real time quantitative PCR. Genome Res, 6, 986-94. https://doi.org/10.1101/gr.6.10.986
  9. Kim YR, Choi JR, Song KS, et al (2002). Evaluation of HER2/ neu status by real-time quantitative PCR in breast cancer. Yonsei Med J, 43, 335-40. https://doi.org/10.3349/ymj.2002.43.3.335
  10. Konigshoff M, Wilhelm J, Bohle RM, et al (2003). HER-2/ neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem, 49, 219-29. https://doi.org/10.1373/49.2.219
  11. Kulka J, Tokes AM, Kaposi-Novak P, et al (2006). Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results. Pathol Oncol Res, 12, 197-204. https://doi.org/10.1007/BF02893412
  12. Lehmann U, Kreipe H (2001). Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffinembedded biopsies. Methods, 25, 409-18. https://doi.org/10.1006/meth.2001.1263
  13. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real- time quantitation PCR and the 2 (-Delta Delta C(T)) Method. Methods, 25, 402-8. https://doi.org/10.1006/meth.2001.1262
  14. Marmor MD, Skaria KB, Yarden Y (2004). Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys, 58, 903-13. https://doi.org/10.1016/j.ijrobp.2003.06.002
  15. Mayr D, Heim S, Weyrauch K, et al (2009). Chromogenic in situ hybridization for HER-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology, 55, 716-23. https://doi.org/10.1111/j.1365-2559.2009.03427.x
  16. Muleris M, Almeida A, Malfoy B, et al (1997) Assignment of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) to human chromosome band 17q21.1 by in situ hybridization. Cytogenet Cell Genet, 76, 34-5. https://doi.org/10.1159/000134507
  17. Owens MA, Horten BC, Da Silva MM (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 5, 63-9. https://doi.org/10.3816/CBC.2004.n.011
  18. Peiro G, Aranda FI, Adrover E, et al (2007). Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance. Hum Pathol, 38, 26-34. https://doi.org/10.1016/j.humpath.2006.07.013
  19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005). Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72. https://doi.org/10.1056/NEJMoa052306
  20. Press MF, Bernstein L, Thomas PA, et al (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol, 15, 2894-904. https://doi.org/10.1200/JCO.1997.15.8.2894
  21. Quenel N, Wafflart J, Bonichon F, et al (1995). The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat, 35, 283-91. https://doi.org/10.1007/BF00665980
  22. Revillion F, Bonneterre J, Peyrat JP (1998). ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 34, 791-808. https://doi.org/10.1016/S0959-8049(97)10157-5
  23. Ring BZ, Seitz RS, Beck R, et al (2006). Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol, 24, 3039-47. https://doi.org/10.1200/JCO.2006.05.6564
  24. Riou G, Mathieu MC, Barrois M, et al (2001) c-erbB-2 (HER-2/ neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer, 95, 266-70. https://doi.org/10.1002/1097-0215(20010720)95:4<266::AID-IJC1045>3.0.CO;2-E
  25. Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
  26. Ross JS, Fletcher JA, Bloom KJ, et al (2004). Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics, 3, 379-98. https://doi.org/10.1074/mcp.R400001-MCP200
  27. Ross JS, Fletcher JA (1998). The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist, 3, 237-52.
  28. Schechter AL, Stern DF, Vaidyanathan L, et al (1984). The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature, 312, 513-6. https://doi.org/10.1038/312513a0
  29. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
  30. Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12. https://doi.org/10.1126/science.2470152
  31. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92. https://doi.org/10.1056/NEJM200103153441101
  32. Smith I, Procter M, Gelber RD, et al ( 2007). HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36. https://doi.org/10.1016/S0140-6736(07)60028-2
  33. Tetu B, Brisson J, Plante V, et al (1998) p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol, 11, 823-30.
  34. Tuma RS (2005). Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst, 97, 870-1. https://doi.org/10.1093/jnci/97.12.870
  35. van de Vijver M (2002). Emerging technologies for HER2 testing. Oncology, 63, 33-8. https://doi.org/10.1159/000066199
  36. Yarden Y (2001). Biology of HER2 and its importance in breast cancer. Oncology, 61, 1-13.
  37. Yaziji H, Goldstein LC, Barry TS, et al (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 291, 1972-7. https://doi.org/10.1001/jama.291.16.1972